 | 
| ||
| home > Aurobindo Pharma > news | |||
| Fitch Assigns ‘A+(ind)/F1+(ind)’ to Aurobindo Pharma’s Bank Loan Facilities
Aurobindo Pharma Limited is pleased to announce that Fitch Ratings has assigned a National Issuer rating of ‘A+(ind)’ with a Stable Outlook to the company. | |||
| 19 Jul 2008
: Aurobindo Pharma Limited is pleased to announce that Fitch Ratings has assigned a National Issuer rating of ‘A+(ind)’ with a Stable Outlook to the company. At the same time it has assigned the following ratings to the company’s bank loan facilities: A+(ind) Outstanding loan limit of INR 1,083 million A+(ind) / F1+(ind) Interchangeable fund-based working capital limits of INR 5,750 million F1+(ind) Non-fund based limits totaling Rs 4,750 million A+(ind) / F1+(ind) Additional interchangeable fund-based working capital limits of INR 2,425 million The ratings reflect APL’s strong revenue growth, its strong foothold in the active pharmaceutical ingredient (API) space, as well as its demonstrated ability in growing its formulation business Rating definitions: A(ind) : National Long-term rating. ‘A’ national ratings denote a strong credit risk relative to other issuers or issues in the same country. However, changes in circumstances or economic conditions may affect the capacity for timely repayment of these financial commitments to a greater degree than for financial commitments denoted by a higher rated category. F1(ind) : National Short-term rating and indicates the strongest capacity for timely payment of financial commitments relative to other issuers or issues in the same country. Under their national rating scale, this rating is assigned to the “best” credit risk relative to all others in the country. Where the creditworthiness is particularly strong, a “+” is added to the assigned rating. About Aurobindo Pharma Limited: Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries. |
|||
| | ||
| home > Aurobindo Pharma > news | |||
 |
|||
| |||